Navigation Links
Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease
Date:1/11/2011

PASADENA, Calif., Jan. 11, 2011 /PRNewswire/ -- Receiving the herpes zoster vaccine was associated with a 55 percent reduced risk of developing shingles, according to a Kaiser Permanente study of 300,000 people that appears in the current issue of the Journal of the American Medical Association.

This retrospective study observed the outcomes of the effectiveness of the herpes zoster vaccine in a large, diverse population of men and women ages 60 years and older. Researchers found a significant reduced risk of shingles across all sub-groups -- those who are healthy as well as those with chronic conditions including diabetes or heart, lung or kidney diseases.

These study findings differ from the clinical trial of the vaccine, which observed its effectiveness on 38,000 participants 60 years of age and older and found it less effective for people older than 75. This new study found a 55 percent reduced risk of shingles among both adults 60 years and older, as well as adults 75 years and older who received the vaccine.

These findings support Centers for Disease Control and Prevention recommendations to offer the vaccine to eligible patients of all ages, including those over 75. Researchers note that additional examination of the vaccine's effect in the oldest group should continue. The herpes zoster vaccine was licensed in 2006, but uptake in the United States remains low: about 10 percent in 2009 in adults 60 years and older.

"Our study shows the vaccine has the potential to prevent tens of thousands of cases of shingles, a painful, lingering disease," said study lead author Hung Fu Tseng, PhD, MPH, a research scientist with the Kaiser Permanente Department of Research & Evaluation in Pasadena, Calif. "We suggest clinicians follow the CDC's recommendations to talk to their patients about the option of vaccination against this serious condition."

There are more than 1 million episodes of shingles every ye
'/>"/>

SOURCE Kaiser Permanente
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
2. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
3. Shingles Pain Treatment Will Benefit More Patients
4. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
5. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
6. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
7. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
8. Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older
9. Oklahoma City Thunder Point Guard Russell Westbrook and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health
10. NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
11. Young Children In Developing World Receive Accelerated Access to Pfizers Prevenar 13 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... Annual Healthcare Conference in New York City . ... for 8:00 am EST (5:00 am PST) on Tuesday December 2, ... accessed via the Investor Relations page of the Depomed website at ... for 30 days on the company,s website. About ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... April 11, 2012  Blue Mountain Hospital has used an electronic ... announced plans to swap out its original technology with an ... "We were lucky to start out as a ... are using simply is not meeting all of our needs," ...
... BAY, Wis., April 11, 2012   IOD Incorporated™, ... health systems, and physician practices, today announced its response ... a proposed rule to delay ICD-10 from October 1, ... http://photos.prnewswire.com/prnh/20111207/CG18689LOGO ) According to HHS regulations ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
(Date:11/22/2014)... Nov. 22, 2014 (HealthDay News) -- The wide variety ... pose a threat for people with food allergies, an ... are so many types of food allergies that it ... the holidays," Dr. Guha Krishnaswamy, director of allergy and ... in a hospital news release. "If you know ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new ... addition, the company has also offered an attracting discount ... online supplier of wedding dresses, UWDress.com is good at ... wedding guest gowns are provided over 20 colors, which ... selection is famous for high quality. Therefore, its sales ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Developers and plugin ... new plugin entitled FCPX 3D Model bringing the impossible to ... Model allows users to add obj files to FCPX enabling ... Studios. “Blurring the line between professional and armature, FCPX 3D ... Pixel Film Studios allows Final Cut Pro X users to ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/21/2014)... CT (PRWEB) November 21, 2014 CRN ... a veteran radio industry sales professional to its award-winning ... brings 30 years of leadership and sales experience to ... and assume the title of Director of Strategy and ... Development, Robert O’Mara. , Heinemann will handle a wide ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2
... WASHINGTON, Oct. 1 Today the Senate ... secured by,Senator John Kerry (D-Mass.) to extend the ... to increase the transition and,commercialization of products developed ... the thousands of firms that participate in the,program ...
... Board Chair, Named Executive ... Chairman, ... ), a biopharmaceutical company focused on the discovery,and development of drugs for ... that Corey Goodman,Ph.D., will step down today as President and Chief Executive ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... from Positive VENT Trial Presented at ERS 17th ... 1 Emphasys Medical Inc.,today announced the submission ... Food and Drug Administration (FDA) requesting regulatory,approval to ... in,the United States. The Zephyr EBV is a ...
... period of time after leaving the foster care system ... those with stable housing situations, according to a report ... Adolescent Medicine, one of the JAMA/Archives journals. Youth who ... leaving the foster care system appear to have more ...
... Behavioral,Health System, a UHS facility, has announced the ... teens in crisis. The new treatment,center is associated ... http://www.highlandsbhs.com ) in Littleton, Colo. Highlands Behavioral ... of Excellence represents an expansion of the Adolescent,Unit ...
Cached Medicine News:Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2
... advancement in supralaryngeal airway management., ,The CobraPLA ... the hypopharynx where it abuts the structure of ... head design of the distal end of the ... epiglottis out of the way, facilitating ventilation through ...
Robertazzi Amber Latex Free Nasal Airways are manufactured from natural amber latex. Soft, flexible maximizing comfort....
Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
Extra soft for patient comfort., ,The Argyle® Nasopharyngeal Airway provides an open airway to make suctioning and bronchoscopy easier, safer, and less traumatic....
Medicine Products: